{"id":"W2944589946","doi":"10.1136/ejhpharm-2019-eahpconf.403","title":"4CPS-254 Biosimilar rituximab – a year beyond","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Kidney Foundation of Canada","keywords":"Biosimilar; Rituximab; Medicine; Discontinuation; Rheumatoid arthritis; Pharmacy; Retrospective cohort study; Internal medicine; Oncology; Lymphoma; Family medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001146247,0.000260568,0.0005460038,0.000101428,0.0001504919,0.00004321252,0.0003992041,0.0004123363,0.01152825],"category_scores_gemma":[0.00005099558,0.000210282,0.000352093,0.0003109396,0.0001806064,0.0002066918,0.0001737478,0.0008703194,0.004863056],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002523202,"about_ca_system_score_gemma":0.00004630303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001040915,"about_ca_topic_score_gemma":0.00003339842,"domain_scores_codex":[0.9975029,0.0005559264,0.0007486133,0.0006549348,0.00008267353,0.0004550002],"domain_scores_gemma":[0.9986966,0.0004415966,0.0002232749,0.0004157591,0.000129863,0.00009291705],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004905067,0.00537224,0.5117972,0.00090528,0.002874013,0.00002995037,0.0004405288,0.00001170162,0.3026558,0.002126279,0.08273812,0.08614381],"study_design_scores_gemma":[0.00615474,0.0003460073,0.01255129,0.00004184309,0.0001842817,0.00002101123,0.0001743546,0.0001558138,0.02220953,0.0007888894,0.9569972,0.0003750001],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9538316,0.002342569,0.00007077746,0.006162045,0.01508047,0.0006314881,0.00009755226,0.0003756444,0.02140792],"genre_scores_gemma":[0.9788494,0.0006247693,0.0007904989,0.01205272,0.0006561105,0.00001157637,0.00006177589,0.00003631345,0.006916836],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8742591,"threshold_uncertainty_score":0.9959118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03496363757777717,"score_gpt":0.3810492240157845,"score_spread":0.3460855864380074,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}